Hyperuricemia: A biomarker of renal hemodynamic impairment

CardioRenal Medicine

Volumn 5, Issue 3, 2015, Pages 175-182

  Susic, Dinko ^a   Frohlich, Edward D ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

Biomarker; Cardiovascular diseases; Hypertension; Intrarenal hemodynamics; Renal diseases; Serum uric acid concentration

Indexed keywords

ALLOPURINOL; ANGIOTENSIN II; BENZIODARONE; BIOLOGICAL MARKER; DIURETIC AGENT; EPLERENONE; NORADRENALIN; OTERACIL; PROBENECID; URIC ACID;

AGING; ALTITUDE; ANTIHYPERTENSIVE THERAPY; ARTERIAL PRESSURE; ARTERIAL STIFFNESS; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DIURETIC THERAPY; DYSLIPIDEMIA; ESSENTIAL HYPERTENSION; GLOMERULUS FILTRATION; GOUT; HUMAN; HYDROSTATIC PRESSURE; HYPERTENSION; HYPERURICEMIA; ISCHEMIC HEART DISEASE; KIDNEY BLOOD FLOW; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY HYPERTROPHY; KIDNEY INJURY; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE ABSORPTION; KIDNEY VASCULAR RESISTANCE; NEPHRITIS; NEPHROLITHIASIS; NONHUMAN; OBESITY; OBSTRUCTIVE UROPATHY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; POLYCYTHEMIA; PREGNANCY DIABETES MELLITUS; PREGNANCY TOXEMIA; PRIORITY JOURNAL; PURINE METABOLISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR DISEASE; STRESS; SYSTOLIC HYPERTENSION; URIC ACID BLOOD LEVEL; URINARY EXCRETION;

EID: 84930898087     PISSN: 16643828     EISSN: 16645502     Source Type: Journal    
DOI: 10.1159/000381317     Document Type: Article

References (61)

1. Stanton JR, Freis ED: Serum uric acid concentration in essential hypertension. Proc Soc Exp Biol Med 1947; 66: 193-194.
2. Mahomed FA: On chronic Bright's disease and its essential symptoms. Lancet 1879; 1: 399-401.
3. Davis N: The cardiovascular and renal relations and manifestations of gout. JAMA 1897; 29: 261-262.
4. Gertler MM, Garn SM, Kevine SA: Serum uric acid in relation to age and physique in health and in coronary heart disease. Ann Intern Med 1951; 34: 1421-1431.
5. Messerli FH, Frohlich ED, Dreslinski GR, Suarez DH, Aristimuno GG: Serum uric acid in essential hypertension: An indicator of renal vascular involvement. Ann Intern Med 1980; 93: 817-821.
6. Kahn HA, Medalie JH, Nefeld JH Riss E, Goldbourt U: The incidence of hypertension and associated factors: The Israel Ischemic Heart Study. Am Heart J 1972; 84: 171-182.
7. Chen JH, Chuang SY, Chen HJ, Yeh WT, Pan WH: Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality. Arthritis Rheum 2009; 61: 225-232.
8. Obermayr RP, Temml C, Gutjahr G, Knechtelsdorfer M, Oberbauer R, Klauser-Braun R: Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol 2008; 19: 2407-2413.
9. Sesoko S, Pegram BL, Willis GW, Frohlich ED: DOCA-salt induced malignant hypertension in spontaneously hypertensive rats. J Hypertens 1984; 2: 49-54.
10. Sanchez-Lozada LG, Tapia E, Santamaría J, Avila-Casado C, Soto V, Nepomuceno T, Rodríguez-Iturbe B, Johnson RJ, Herrera-Acosta J: Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int 2005; 67: 237-247.
11. Feig DI, Kung DH, Johnson RJ: Uric acid and cardiovascular risk. N Engl J Med 2008; 359: 1811-1821.
12. Frohlich ED: Uric acid: A risk factor for coronary heart disease. JAMA 1993; 270: 378-379.
13. Zoccali C, Mallamaci F: Uric acid, hypertension, and cardiovascular and renal complications. Curr Hypertens Rep 2013; 15: 531-537.
14. Niskanen LK, Laaksonen DE, Nyyssönen K, Alfthan G, Lakka HM, Lakka TA, Salonen JT: Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle aged man: A prospective cohort study. Arch Intern Med 2004; 164: 1546-1551.
15. Wu X, Muzny DM, Lee CC, Caskey CT: Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol 1992; 34: 78-84.
16. Watanabe S, Kang DH, Feng L, Nakagawa T, Kanellis J, Lan H, Mazzali M, Johnson RJ: Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 2002; 40: 355-360.
17. Richette P, Bardin T: Gout. Lancet 2010; 375: 318-328.
18. Zhou X, Matavelli L, Frohlich ED: Uric acid: its relationship to renal hemodynamics and the renal renin-angiotensin system. Curr Hypert Rep 2006; 8: 120-124.
19. Bellomo G: Uric acid and chronic kidney disease: A time to act? World J Nephrol 2013; 2: 17-25.
20. Pascual E, Perdiguero M: Gout, diuretics and the kidney. Ann Rheum Dis 2006; 65: 981-982.
21. Alvarez-Lario B, Maccaron-Vicente J: Is there anything good in uric acid? Q J Med 2011; 104: 1015-1024.
22. Glantzuonis G, Tsimoyiannis E, Kappas A, Galaris D: Uric acid and oxidative stress. Curr Pharm Des 2005; 11: 4145-4151.
23. Sofaer JA, Emery AEH: Genes for super-intelligence. J Med Genet 1981; 18: 410-413.
24. Toncev G, Milicic B, Toncev S, Samardzic G: Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol 2002; 9: 221-226.
25. Chen H, Mosley TH, Alonso A, Huang X: Plasma urate and Parkinson's disease in the atherosclerosis risk in communities (ARIS) study. Am J Epidemiol 2010; 172: 666-670.
26. Irizarry MC, Raman R, Schwarzschild MA, Becerra LM, Thomas RG, Peterson RC, Ascherio A, Aisen PS: Plasma urate and progression of mild cognitive impairment. Neurodegener Dis 2009; 6: 23-28.
27. Johnson RJ, Rideout BA: Uric acid and diet-insights into the epidemic of cardiovascular disease. N Engl J Med 2004; 350: 1071-1073.
28. Francischetti A, Ono H, Frohlich ED: Renoprotective effects of felodipine and/or enalapril in spontaneously hypertensive rats with and without L-NAME. Hypertension 1998; 31: 795-801.
29. Nakamura Y, Ono H, Zhou X, Frohlich ED: Angiotensin type 1 receptor antagonism and ACE inhibition produce produce similar renoprotection in N-nitro-L-arginine methylester/spontaneously hypertensive rats. Hypertension 2001; 37: 1262-1267.
30. Zhou X, Matavelli LC, Ono H, Frohlich ED: Superiority of combination of thazide with angiotensin-converting enzyme inhibitor or AT 1-receptor blocker over thiazide alone on renoprotection in L-NAME/SHR. Am J Physiol Renal Physiol 2005; 289:F871-F879.
31. Uchino K, Nishikimi T, Frohlich ED: 1-Adrenergic receptor blockade reduces afferent and efferent glomerular arteriolar resistances in SHR. Am J Physiol 1991; 261:R576-R580.
32. Ono H, Ono Y, Frohlich ED: Nitric oxide synthase inhibition in spontaneously hypertensive rats. Systemic, renal, and glomerular hemodynamics. Hypertension 1995; 26: 249-255.
33. Komatsu K, Frohlich ED, Ono H, Ono Y, Numabe A, Willis GW: Glomerular dynamics and morphology of aged spontaneously hypertensive rats: effects of angiotensin-converting enzyme inhibition. Hypertension 1995; 25: 207-213.
34. Zhou X, Ono H, Ono Y, Frohlich ED: Aldosterone antagonism ameliorates proteinuria and nephrosclerosis independent of glomerular dynamics in L-NAME/SHR model. Am J Nephrol 2004; 24: 242-249.
35. Wu X, Wakamiya M, Vaishnav S, Geske R, Montgomery C Jr, Jones P, Bradley A, Caskey CT: Hyperuricemia and urate nephropathy in urate oxidase-deficient mice. Proc Natl Acad Sci USA 1994; 91: 742-746.
36. Mazzali M, Huges J, Kim YG, Jefferson JA, Kang DH, Gordon KL, Lan HY, Kivlighn S, Johnson RJ: Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001; 38: 1101-1106.
37. Sanchez-Lozada LG, Tapia E, Santamaria J, Avila-Casado C, Soto V, Nepomuceno T, Rodriguez-Iturbe B, Johnson RJ, Herrera-Acosta J: Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int 2005; 67: 237-247.
38. Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, Kang DH, Gordon LL, Watanabe S, Nakagawa T, Lan HY, Johnson RJ: Hyperuricemia induces primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 2002; 282:F991-F997.
39. Nakagawa T, Mazzali M, Kang DH, Kanellis J, Watanabe S, Sanchez-Lozada LG, Rodriguez-Iturbe B, Herrera-Acosta J, Johnson RJ: Hyperuricemia causes glomerular hypertrophy in the rat. Am J Nephrol 2003; 23: 2-7.
40. Kang DH, Nakagawa T, Feng L, Johnson RJ: Nitric oxide modulates vascular disease in the remnant kidney model. Am J Pathol 2002; 161: 239-248.
41. Khosla UM, Zharikov S, Finch J: Hyperuricemia induces endothelial dysfunction. Kidney Int 2005; 67: 1739-1742.
42. Kanellis J, Watanabe S, Li JH, Kang DH, Li P, Nakagawa T, Wamsley A, Sheikh-Hamad D, Lan HY, Feng L, Johnson RJ: Uric acid simulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 2003; 41: 1287-1293.
43. Feig DI, Mazzali M, Kang DH, Nakagawa T, Price K, Kannelis J, Johnson RJ: Serum uric acid: A risk factor and a target for treatment? J Am Soc Nephrol 2006; 17:S69-S73.
44. Durante P, Chavez M, Perez M, Romero F, Rivera F: Effects of uric acid in spontaneously hypertensive rats. Life Sci 2010; 86: 957-964.
45. Johnson RJ, Sanchez-Lozada LG, Mazzali M, Feig DI, Kanbay M, Sautin YY: What are the key arguments against uric acid as a true risk factor for hypertension? Hypertension 2013; 61: 948-951.
46. Ferris TF, Gorden P: Effect of angiotensin and norepinephrine upon urate clearance in man. Am J Med 1968; 44: 359-365.
47. Kobrin I, Frohlich ED, Ventura O, Messerli FH: Renal involvement follows cardiac enlargement in essential hypertension. Arch Intern Med 1986; 146: 272-276.
48. Nunez BD, Frohlich ED, Garavaglia GE, Schmieder RE, Nunez MM: Serum uric acid in renovascular hypertension. Am J Med Sci 1987; 294: 419-422.
49. Culleton BF, Larson MG, Kannel WB, Levy D: Serum uric acid and risk for cardiovascular disease and death: The Framingham Heart Study. Ann Intern Med 1999; 131: 7-13.
50. Krishnan E, Kwoh CK, Schumacher HR, Kuller L: Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension 2007; 49: 298-303.
51. Ben-Dov IZ, Kark JD: Serum uric acid is a GFR-independent long-term predictor of acute and chronic renal insufficiency: The Jerusalem Lipid Research cohort study. Nephrol Dial Transplant 2011; 26: 2558-2566.
52. Oh CM, Park SK, Ryoo JH: Serum uric acid level is associated with the development of microlabuminuria in Korean men. Eur J Clin Invest 2014; 44: 4-12.
53. Feig DI: Serum uric acid and the risk of hypertension and chronic kidney disease. Curr Opin Rheumatol 2014; 26: 176-185.
54. Feig DI, Soletsky B, Johnson RJ: Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: A randomized trial. JAMA 2008; 300: 924-932.
55. Soletsky B, Feig DI: Uric acid reduction rectifies prehypertension in obese adolescents. Hypertension 2012; 60: 1148-1156.
56. Chaudhary K, Malhotra K, Sowers J, Aroor A: Uric acid-key ingredient in the recipe for cardiorenal metabolic syndrome. Cardiorenal Med 2013; 3: 208-220.
57. Gigante A, Liberatori M, Gasperini ML, Sardo L, Di Mario F, Dorelli B, Barbano B, Rosato E, Rosi Fanelli F, Amoroso A: Prevalence and clinical features of patients with cardiorenal syndrome admitted to an internal medicine ward. Cardiorenal Med 2014; 4: 88-94.
58. Jia G, Aroor AR, Sowers JR: Arterial stiffness: A nexus between cardiac and renal disease. Cardiorenal Med 2014; 4: 60-71.
59. Lee CT, Huang CC, Hsu CY, Chiou TT, Ng HY, Wu CH, Kuo WH, Lee YT: Calcification of aortic arch predicts cardiovascular and all-cause mortality in chronic hemodialysis patients. Cardiorenal Med 2014; 4: 34-42.
60. Kushiyama A, Tanaka K, Hara S, Kawazu S: Linking uric acid metabolism to diabetic complications. World J Diabetes 2014; 5: 787-795.
61. Richette P, Perez-Ruiz F, Doherty M, Jansen TL, Nuki G, Pascual E, Punzi L, So AK, Bardin T: Improving cardiovascular and renal outcomes in gout: what should we target? Nat Rev Rheumatol 2014; 10: 654-661.